LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial.

    Rizas, Konstantinos D / Freyer, Luisa / Sappler, Nikolay / von Stülpnagel, Lukas / Spielbichler, Peter / Krasniqi, Aresa / Schreinlechner, Michael / Wenner, Felix N / Theurl, Fabian / Behroz, Amira / Eiffener, Elodie / Klemm, Mathias P / Schneidewind, Annika / Zens, Martin / Dolejsi, Theresa / Mansmann, Ulrich / Massberg, Steffen / Bauer, Axel

    Nature medicine

    2022  Volume 28, Issue 9, Page(s) 1823–1830

    Abstract: Digital smart devices have the capability of detecting atrial fibrillation (AF), but the efficacy of this type of digital screening has not been directly compared to usual care for detection of treatment-relevant AF. In the eBRAVE-AF trial ( NCT04250220 ) ...

    Abstract Digital smart devices have the capability of detecting atrial fibrillation (AF), but the efficacy of this type of digital screening has not been directly compared to usual care for detection of treatment-relevant AF. In the eBRAVE-AF trial ( NCT04250220 ), we randomly assigned 5,551 policyholders of a German health insurance company who were free of AF at baseline (age 65 years (median; interquartile range (11) years, 31% females)) to digital screening (n = 2,860) or usual care (n = 2,691). In this siteless trial, for digital screening, participants used a certified app on their own smartphones to screen for irregularities in their pulse waves. Abnormal findings were evaluated by 14-day external electrocardiogram (ECG) loop recorders. The primary endpoint was newly diagnosed AF within 6 months treated with oral anti-coagulation by an independent physician not involved in the study. After 6 months, participants were invited to cross-over for a second study phase with reverse assignment for secondary analyses. The primary endpoint of the trial was met, as digital screening more than doubled the detection rate of treatment-relevant AF in both phases of the trial, with odds ratios of 2.12 (95% confidence interval (CI), 1.19-3.76; P = 0.010) and 2.75 (95% CI, 1.42-5.34; P = 0.003) in the first and second phases, respectively. This digital screening technology provides substantial benefits in detecting AF compared to usual care and has the potential for broad applicability due to its wide availability on ordinary smartphones. Future studies are needed to test whether digital screening for AF leads to better treatment outcomes.
    MeSH term(s) Atrial Fibrillation/diagnosis ; Atrial Fibrillation/drug therapy ; Child ; Delivery of Health Care ; Electrocardiography ; Female ; Humans ; Male ; Mass Screening ; Smartphone
    Language English
    Publishing date 2022-08-28
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-022-01979-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Rationale and design of a digital trial using smartphones to detect subclinical atrial fibrillation in a population at risk: The eHealth-based bavarian alternative detection of Atrial Fibrillation (eBRAVE-AF) trial.

    Freyer, Luisa / von Stülpnagel, Lukas / Spielbichler, Peter / Sappler, Nikolay / Wenner, Felix / Schreinlechner, Michael / Krasniqi, Aresa / Behroz, Amira / Eiffener, Elodie / Zens, Martin / Dolejsi, Theresa / Massberg, Steffen / Rizas, Konstantinos D / Bauer, Axel

    American heart journal

    2021  Volume 241, Page(s) 26–34

    Abstract: Current guidelines recommend opportunistic screening for subclinical atrial fibrillation (AF) taking advantage of e-health-based technologies. However, the efficacy of a fully scalable e-health-based strategy for AF detection in a head-to-head comparison ...

    Abstract Current guidelines recommend opportunistic screening for subclinical atrial fibrillation (AF) taking advantage of e-health-based technologies. However, the efficacy of a fully scalable e-health-based strategy for AF detection in a head-to-head comparison with routine symptom-based screening is unknown. eBRAVE-AF is an investigator-initiated, digital, prospective, randomized, siteless, open-label, cross-over study to evaluate an e-health-based strategy for detection of AF in a real-world setting. 67,488 policyholders of a large German health insurance company (Versicherungskammer Bayern, Germany) selected by age ≥ 50 years and a CHA
    MeSH term(s) Asymptomatic Diseases/epidemiology ; Atrial Fibrillation/complications ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/drug therapy ; Atrial Fibrillation/epidemiology ; Cross-Over Studies ; Female ; Germany/epidemiology ; Humans ; Insurance, Health/statistics & numerical data ; Male ; Middle Aged ; Mobile Applications ; Monitoring, Ambulatory/instrumentation ; Monitoring, Ambulatory/methods ; Randomized Controlled Trials as Topic/methods ; Smartphone ; Telemedicine/instrumentation ; Telemedicine/methods
    Language English
    Publishing date 2021-07-09
    Publishing country United States
    Document type Clinical Trial Protocol ; Journal Article
    ZDB-ID 80026-0
    ISSN 1097-6744 ; 0002-8703
    ISSN (online) 1097-6744
    ISSN 0002-8703
    DOI 10.1016/j.ahj.2021.06.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Telemedical cardiac risk assessment by implantable cardiac monitors in patients after myocardial infarction with autonomic dysfunction (SMART-MI-DZHK9): a prospective investigator-initiated, randomised, multicentre, open-label, diagnostic trial.

    Bauer, Axel / Sappler, Nikolay / von Stülpnagel, Lukas / Klemm, Mathias / Schreinlechner, Michael / Wenner, Felix / Schier, Johannes / Al Tawil, Amani / Dolejsi, Theresa / Krasniqi, Aresa / Eiffener, Elodie / Bongarth, Christa / Stühlinger, Markus / Huemer, Martin / Gori, Tommaso / Wakili, Reza / Sahin, Riza / Schwinger, Robert / Lutz, Matthias /
    Luik, Armin / Gessler, Nele / Clemmensen, Peter / Linke, Axel / Maier, Lars S / Hinterseer, Martin / Busch, Mathias C / Blaschke, Florian / Sack, Stefan / Lennerz, Carsten / Licka, Manuela / Tilz, Roland R / Ukena, Christian / Ehrlich, Joachim R / Zabel, Markus / Schmidt, Georg / Mansmann, Ulrich / Kääb, Stefan / Rizas, Konstantinos D / Massberg, Steffen

    The Lancet. Digital health

    2021  Volume 4, Issue 2, Page(s) e105–e116

    Abstract: Background: Cardiac autonomic dysfunction after myocardial infarction identifies patients at high risk despite only moderately reduced left ventricular ejection fraction. We aimed to show that telemedical monitoring with implantable cardiac monitors in ... ...

    Abstract Background: Cardiac autonomic dysfunction after myocardial infarction identifies patients at high risk despite only moderately reduced left ventricular ejection fraction. We aimed to show that telemedical monitoring with implantable cardiac monitors in these patients can improve early detection of subclinical but prognostically relevant arrhythmic events.
    Methods: We did a prospective investigator-initiated, randomised, multicentre, open-label, diagnostic trial at 33 centres in Germany and Austria. Survivors of acute myocardial infarction with left ventricular ejection fraction of 36-50% had biosignal analysis for assessment of cardiac autonomic function. Patients with abnormal periodic repolarisation dynamics (≥5·75 deg
    Findings: Between May 12, 2016, and July 20, 2020, 1305 individuals were screened and 400 patients at high risk were randomly assigned (median age 64 years [IQR 57-73]); left ventricular ejection fraction 45% [40-48]) to telemedical monitoring with implantable cardiac monitors (implantable cardiac monitor group; n=201) or conventional follow-up (control group; n=199). During median follow-up of 21 months, serious arrhythmic events were detected in 60 (30%) patients of the implantable cardiac monitor group and 12 (6%) patients of the control group (hazard ratio 6·33 [IQR 3·40-11·78]; p<0·001). An improved detection rate by implantable cardiac monitors was observed for all types of serious arrhythmic events: atrial fibrillation 6 min or longer (47 [23%] patients vs 11 [6%] patients; p<0·001), atrioventricular block class IIb or higher (14 [7%] vs 0; p<0·001) and ventricular tachycardia or ventricular fibrillation (nine [4%] patients vs two [1%] patients; p=0·054).
    Interpretation: In patients at high risk after myocardial infarction and cardiac autonomic dysfunction but only moderately reduced left ventricular ejection fraction, telemedical monitoring with implantable cardiac monitors was highly effective in early detection of subclinical, prognostically relevant serious arrhythmic events.
    Funding: German Centre for Cardiovascular Research (DZHK) and Medtronic Bakken Research Center.
    MeSH term(s) Aged ; Arrhythmias, Cardiac/diagnosis ; Austria ; Female ; Germany ; Humans ; Male ; Middle Aged ; Monitoring, Physiologic/methods ; Myocardial Infarction/complications ; Myocardial Infarction/physiopathology ; Prospective Studies ; Risk Assessment/methods ; Telemedicine/methods
    Language English
    Publishing date 2021-12-03
    Publishing country England
    Document type Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ISSN 2589-7500
    ISSN (online) 2589-7500
    DOI 10.1016/S2589-7500(21)00253-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top